Now that you have been diagnosed with breast cancer, learn how the SYMPHONY™ personalized genomic breast cancer profile can help you take the next step.
No two tumors are alike….

Why should they be treated the same?

With today’s medicine we now have technology available that can determine the biology of your specific tumor type. This information, called a genomic profile, is used to tailor your cancer treatment plan around your specific tumor biology to give you the best outcome with the fewest side effects.

Matching an individual’s biology with a selected therapy is called personalized medicine. Looking at the genes in your tumor and determining how the genes are functioning is the first step in personalizing your medical plan. Once the genomic test has been performed, that information will tell you and your doctor how your tumor is behaving and to which therapy it will best respond.

Your doctor thinks that the Symphony personalized breast cancer genomic profile will help guide your treatment plan, which is why you were given this brochure.

Oprah Winfrey recognized Dr. Laura van ’t Veer, Co-founder of Agendia, for her work on MammaPrint as one of the “Five Biggest Health Breakthroughs by Women Scientists” in “0” Magazine

TIME Magazine chose MammaPrint as one of the “Five Best Healthcare Inventions of the Year” naming it “Cancer’s Crystal Ball.”
Personalized Medicine:

Personalized medicine for your breast cancer begins with Symphony genomic breast cancer profile. This is a suite of four genomic tests that will provide information specific to your tumor about how aggressive it is behaving and which molecular pathways are driving its growth. This knowledge, coupled with your own medical history and clinical pathology, will help determine which treatment plan is best for YOU. It will help determine if you will benefit from chemotherapy, hormonal therapy, or other combinations of treatments.

The SYMPHONY genomic profile will guide your treatment decisions and help answer the following questions:

- Will you benefit from chemotherapy?
- Based on your molecular subtype, are there specific combinations of therapy that will be more selective in treating your type of cancer?
- Will your tumor respond to hormonal therapy?
- Are there alternate therapy options if your tumor does not respond?
What is the SYMPHONY personalized breast cancer Profile?

The SYMPHONY personalized genomic profile for breast cancer began as one test, MammaPrint®. It now includes 4 tests, MammaPrint, BluePrint™, TargetPrint®, and TheraPrint®. Each of these tests looks at different gene sets in your tumor and provides in-depth information about specific tumor characteristics. Your tumor characteristics will help direct your personal treatment plan.

**MammaPrint** studies 70 prognostic genes that determine your risk of recurrence. You will receive a definitive result: Low Risk or High Risk. There are no intermediate results that may lead to further indecision. Results are given based on what would happen if you had no treatment at all. Your test results will come back as having either a High Risk or Low Risk of recurrence.

If you are in the Low Risk category, you have a 10% chance of your cancer returning within 10 years after surgery with no adjuvant hormonal or chemotherapy. There is little, if any, benefit to getting chemotherapy. By adding hormonal therapy alone your risk can be lowered to about 5% chance of recurrence.

If you are in the High Risk category, you have a 29% chance of your cancer returning within the next 10 years and you should consider chemotherapy as part of your regimen. High Risk patients can be separated into subtypes, which can further refine your treatment plan.
BluePrint investigates 80 genes that identify the molecular subtype of your tumor so that you and your doctor can choose the drug combination that offers the best therapeutic result for your specific tumor type. There are four main subtypes: HER2 (also called ERBB2), basal, luminal A and luminal B. Each of these molecular subtypes respond differently to various therapies. By knowing your subtype, your doctor can select the most effective treatment for your type of cancer.

TargetPrint quantifies ER, PR, HER2 receptor status by measuring mRNA to more precisely determine your receptor status. Research has shown that mRNA measurement of these receptors are linked to improved outcomes over traditional staining methods for these receptors. Your receptor status will determine if your tumor will respond to targeted therapy.

TheraPrint looks at an individualized genomic fingerprint of the patient’s tumor with gene expression results for 55 biomarkers and variant analysis results for 4 genes that can help determine an alternate course of therapy, if necessary. TheraPrint is used for women with advanced or metastatic cancer.

All of these genomic tests combined, called SYMPHONY, will provide you and your doctor with the most comprehensive information available to help guide your decision making process for treatment planning.

SYMPHONY™
Personalized Breast Cancer Genomic Profile
How were the genomic tests in SYMPHONY discovered?

As published in Nature, the SYMPHONY genomic profile was developed by taking samples from a population of thousands untreated breast cancer tumors whose 10 year outcome was known. Using these untreated breast cancer tumors, they looked at all 25,000 human genes in order to learn which ones are involved in breast cancer metastasis. Researchers were able to separate the tumors into two categories: those tumors that came back and those tumors that did not recur within 10 years. By comparing the gene expression of the two groups of tumor cells, they were able to identify the most prognostic genes involved in breast cancer. A precise bioinformatics algorithm was used to determine the 70 gene expression signature that clearly and accurately identified those tumors that would likely recur in 10 years and those that would not1.

MammaPrint is the only gene expression profile cleared by the FDA to assess the individual risk of breast cancer metastasis. As a truly “next generation” diagnostic test, MammaPrint takes advantage of the progress made by the Human Genome Project and recent advances in multigene microarray technology to analyze the complex biology of a tumor and provide you and your clinician with detailed information about your cancer1-3.

How does SYMPHONY genomic tests differ from genetic testing?

Genetic testing refers to the study of genes and their role in inheritance; how certain traits or conditions are passed from one generation to the next, such as BRCA. Genetic tests assess the likelihood of your getting cancer.

On the other hand, genomic tests study the genes of a tumor once you already have cancer. Genomic tests look at the behavior of the tumor to predict its response.

SYMPHONY is a suite of genomic tests analyzing a profile of over 1300 genes involved in the activity of a specific breast cancer tumor. It provides a genomic signature of the complex biology of your tumor to assess the risk of the cancer coming back and helps determine the specific treatment that YOU need.
How MammaPrint was validated?

MammaPrint has been validated in independent studies in more than 6,000 breast cancer patients at major cancer centers in Europe and the U.S. The results have been published in prestigious journals with external peer scientific review, such as New England Journal of Medicine, Lancet Oncology, Journal of the National Cancer Institute, Clinical Cancer Research and Breast Cancer Research and Treatment.

To date, more than 30,000 early stage breast cancer patients, like you, have chosen Symphony to evaluate their individual risk of recurrence.

Why is it important that the test be cleared by the FDA?

Since you and your doctor will be making life decisions about your treatment based on the results of the test, you cannot underestimate the importance of the review and approval by a regulatory body. MammaPrint being cleared as In Vitro Diagnostic Multivariate Index Assay (IVDMIA) by the United States Food and Drug Administration provides confidence in its safety and effectiveness. The FDA label states that, as a diagnostic tool, MammaPrint has 98.9% reproducibility for classifying patients as “Low Risk” or “High Risk”.

MammaPrint is the only gene expression test for breast cancer currently available in the United States that has met the stringent criteria for IVDMIA clearance by FDA.

“The clearance of the MammaPrint test marks a step forward in the effort to join molecular medicine with current medical care. MammaPrint results will provide patients and their caregivers with more information about the prospects for disease outcome. This information will serve as a backup to making decisions about treatment.” (FDA)

-Dr. Andrew C. von Eschenbach, M.D., Former Commissioner of U.S. Food and Drug Administration
What should I do to have the SYMPHONY breast cancer genomic profile ordered for me?

During your preliminary consultation, ask your doctor to order the SYMPHONY suite of tests so that you can make more informed decisions about treatment options for you.

Where are the SYMPHONY tests performed?

The tests are performed in state-of-the-art Clinical Laboratory Improvement Amendments (CLIA) and the College of Pathology (CAP) certified, registered, and compliant genomics laboratories in Irvine, California, USA and in Amsterdam, The Netherlands.

How long will it take to get my SYMPHONY results?

We understand the urgency of the test result and its impact on treatment decisions. All tests are performed with a fast turnaround time while maintaining the strictest quality control. The test results are delivered to your physician approximately 10 working days after the sample submission.

knowYour breast cancer.com
**Will my insurance cover the cost of SYMPHONY?**

Currently Australian insurance companies are not funding the financial costs of these tests. However, if you apply to your health insurance company in writing, and include a letter of support from your specialist, then your insurance company may consider a part payment to support you in your endeavours.

**What if I don’t have insurance or my insurance doesn’t cover it?**

Genome Investigation is a compassionate company offering a range of financial assistance options for you to consider. For more details, please contact Genome Investigation’s billing department on (+61) 2 8004 0075, or info@mammaprint.com.au.

**Where can I find more information about breast cancer and the SYMPHONY genomic profile?**

For more information please visit www.knowYOURbreastcancer.com or scan the barcode below with your smartphone.
SYMPHONY is the most comprehensive genomic profile that can definitively tell you the probability of recurrence and responsiveness to chemotherapy based on your molecular subtype.

REFERENCES:
15) Kok M, Koornstra R, Mook S, et al., Submitted
**Agenda Symphony Suite Pricing & Payment**  
*(Prices as at 1st February 2014)*

<table>
<thead>
<tr>
<th>Service</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>MammaPrint Service (without a Symphony Service)</td>
<td>$USD4,200.00</td>
</tr>
<tr>
<td>TargetPrint Service (without a Symphony Service)</td>
<td>$USD1,500.00</td>
</tr>
<tr>
<td>BluePrint Service (without a Symphony Service)</td>
<td>$USD4,250.00</td>
</tr>
</tbody>
</table>

**Special Australia Introductory Price for 2014 –**  
MammaPrint Symphony (MammaPrint, BluePrint & TargetPrint) for $USD4,200.00

<table>
<thead>
<tr>
<th>Service</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Theraprint Service</td>
<td>$USD5,200.00</td>
</tr>
<tr>
<td>Coloprint Service</td>
<td>$USD4,250.00</td>
</tr>
</tbody>
</table>

*Payments can be made to Agenda Inc (into their USA Wells Fargo Bank account by international transfer). Alternatively, payments can be made direct to the Genome Investigation Pty Ltd (Australia) ANZ bank account in Australian dollars, in an amount equivalent to the above prices in US dollars. Please contact Genome Investigation Pty Ltd on (+61) 2 8004 0075 for more information.*
Advantages of SYMPHONY breast cancer profile:

• The most comprehensive information about your cancer type, which is vital for making decisions about your treatment.

• Definitive result in 100% of cases. No Intermediate results.

• It can be done at any point during your treatment planning.

• Only test of its kind cleared by the U.S. FDA.

• Provides risk of recurrence, potential response to chemotherapy, and determines if targeted therapy is right for you.